{
    "hands_on_practices": [
        {
            "introduction": "The ability of a cytotoxic T lymphocyte to recognize and eliminate an infected cell depends critically on the number of specific pathogenic peptide-MHC (pMHC) complexes displayed on the cell surface. This quantitative exercise  challenges you to build a kinetic model from first principles, connecting the entire antigen presentation pathway—from proteasomal peptide generation to cell surface complex stability. By deriving and evaluating an expression for the steady-state abundance of pMHC, you will gain a deeper appreciation for how the rates of production, transport, binding, and decay collectively determine the visibility of an infected cell to the immune system.",
            "id": "4696770",
            "problem": "A cytotoxic T lymphocyte (CTL) recognizes infected cells by scanning the cell surface for peptide–Major Histocompatibility Complex class I (MHC I) complexes that present intracellular pathogen-derived epitopes. Consider a single infected human cell presenting a specific viral epitope through the MHC I pathway. Assume the following scientifically grounded facts as the fundamental base:\n\n- Proteasomal processing generates epitope peptides in the cytosol at a rate of $R$ peptides per second per cell.\n- The Transporter associated with Antigen Processing (TAP) transfers a fraction $f$ of these peptides into the endoplasmic reticulum (ER).\n- In the ER, a peptide is subject to two independent, memoryless (exponential) processes: degradation at rate $d$ (per second) and binding to a free MHC I molecule. For a single peptide, the binding hazard is proportional to the number of free MHC I molecules, with proportionality constant $\\alpha$ (per second per free MHC I molecule). If there are $M_{\\text{free}}$ free MHC I molecules, the instantaneous binding rate for a peptide is $\\lambda_{\\text{bind}} = \\alpha M_{\\text{free}}$.\n- Once formed, a peptide–MHC I complex is lost through dissociation with rate constant $k_{\\text{off}}$ and through internalization from the plasma membrane with rate constant $k_{\\text{int}}$. The dissociation rate relates to the measured complex half-life $t_{1/2}$ via $k_{\\text{off}} = \\ln(2)/t_{1/2}$.\n\nUsing only these facts, derive from first principles an expression for the expected steady-state abundance of the epitope-specific peptide–MHC I complexes on the cell surface. Then evaluate it for the following parameter values that are appropriate for human lymphocytes:\n\n- Proteasomal epitope generation rate: $R = 100$ peptides per second per cell.\n- TAP transport efficiency: $f = 0.30$.\n- ER peptide degradation rate: $d = 0.50$ per second.\n- Free MHC I molecules available to bind this epitope: $M_{\\text{free}} = 1.0 \\times 10^{4}$ molecules per cell.\n- Effective association proportionality constant: $\\alpha = 1.0 \\times 10^{-4}$ per second per free MHC I molecule.\n- Peptide–MHC I complex half-life: $t_{1/2} = 3600$ seconds.\n- MHC I internalization rate: $k_{\\text{int}} = 1.0 \\times 10^{-4}$ per second.\n\nAssume steady state, spatial homogeneity in the ER and on the plasma membrane, independence of the exponential loss processes, and that $M_{\\text{free}}$ is not appreciably perturbed by the binding of this single epitope species. Report the final expected number of epitope-specific peptide–MHC I complexes per cell, rounded to three significant figures, and express the answer in molecules per cell.\n\nIn addition, briefly identify two biological factors or assumptions under which this estimate would be expected to fail. Your identification does not alter the required numerical final answer.",
            "solution": "The problem statement is scientifically grounded, well-posed, and objective. It presents a standard kinetic model of antigen presentation, providing all necessary parameters and assumptions to derive a unique, meaningful solution. The problem is therefore deemed valid.\n\nThe solution is derived by modeling the system as a two-stage kinetic process at steady state.\n\nFirst, we consider the population of epitope peptides within the endoplasmic reticulum (ER). Let $P_{\\text{ER}}$ be the number of these peptides in the ER. The rate of change of $P_{\\text{ER}}$ is given by the balance between their influx from the cytosol and their loss due to degradation or binding to Major Histocompatibility Complex class I (MHC I) molecules.\n\nThe rate of epitope generation by the proteasome is $R$. A fraction $f$ is transported into the ER by the Transporter associated with Antigen Processing (TAP). Thus, the influx rate of peptides into the ER is $fR$.\nPeptides in the ER are subject to two independent first-order loss processes:\n1. Degradation, with a rate constant $d$. The total degradation rate for the population $P_{\\text{ER}}$ is $d P_{\\text{ER}}$.\n2. Binding to a free MHC I molecule. The hazard rate for a single peptide is given as $\\lambda_{\\text{bind}} = \\alpha M_{\\text{free}}$, where $M_{\\text{free}}$ is the number of available free MHC I molecules and $\\alpha$ is the proportionality constant. The total binding rate for the population $P_{\\text{ER}}$ is $(\\alpha M_{\\text{free}}) P_{\\text{ER}}$.\n\nThe differential equation describing the number of peptides in the ER is:\n$$ \\frac{dP_{\\text{ER}}}{dt} = fR - dP_{\\text{ER}} - (\\alpha M_{\\text{free}})P_{\\text{ER}} = fR - (d + \\alpha M_{\\text{free}})P_{\\text{ER}} $$\nAt steady state, $\\frac{dP_{\\text{ER}}}{dt} = 0$. Solving for the steady-state peptide population, $P_{\\text{ER,ss}}$:\n$$ fR = (d + \\alpha M_{\\text{free}})P_{\\text{ER,ss}} $$\n$$ P_{\\text{ER,ss}} = \\frac{fR}{d + \\alpha M_{\\text{free}}} $$\nThe rate of formation of new peptide-MHC I complexes in the ER, which we denote as $\\text{Rate}_{\\text{form}}$, is the total binding rate at steady state:\n$$ \\text{Rate}_{\\text{form}} = (\\alpha M_{\\text{free}}) P_{\\text{ER,ss}} = \\frac{fR \\alpha M_{\\text{free}}}{d + \\alpha M_{\\text{free}}} $$\nThis expression represents the number of new complexes produced per second.\n\nNext, we consider the population of these specific peptide-MHC I complexes on the cell surface, denoted by $C_{\\text{surf}}$. We assume that the transport of newly formed complexes from the ER to the cell surface is rapid and not rate-limiting. Therefore, the rate of arrival of complexes at the surface is equal to their formation rate, $\\text{Rate}_{\\text{form}}$.\n\nThese surface complexes are lost through two independent processes:\n1. Dissociation of the peptide, with rate constant $k_{\\text{off}}$.\n2. Internalization of the complex from the plasma membrane, with rate constant $k_{\\text{int}}$.\n\nSince these are independent, first-order processes, the total loss rate constant for a single complex is $k_{\\text{loss}} = k_{\\text{off}} + k_{\\text{int}}$. The total rate of loss for the surface population $C_{\\text{surf}}$ is $(k_{\\text{off}} + k_{\\text{int}})C_{\\text{surf}}$.\n\nThe differential equation for the number of surface complexes is:\n$$ \\frac{dC_{\\text{surf}}}{dt} = \\text{Rate}_{\\text{form}} - (k_{\\text{off}} + k_{\\text{int}})C_{\\text{surf}} $$\nAt steady state, $\\frac{dC_{\\text{surf}}}{dt} = 0$. Solving for the steady-state abundance of surface complexes, $C_{\\text{surf,ss}}$:\n$$ \\text{Rate}_{\\text{form}} = (k_{\\text{off}} + k_{\\text{int}})C_{\\text{surf,ss}} $$\n$$ C_{\\text{surf,ss}} = \\frac{\\text{Rate}_{\\text{form}}}{k_{\\text{off}} + k_{\\text{int}}} $$\nSubstituting the expression for $\\text{Rate}_{\\text{form}}$, we obtain the final analytical expression:\n$$ C_{\\text{surf,ss}} = \\left( \\frac{1}{k_{\\text{off}} + k_{\\text{int}}} \\right) \\left( \\frac{fR \\alpha M_{\\text{free}}}{d + \\alpha M_{\\text{free}}} \\right) $$\nThe dissociation rate constant $k_{\\text{off}}$ is related to the half-life $t_{1/2}$ by $k_{\\text{off}} = \\frac{\\ln(2)}{t_{1/2}}$. Substituting this gives:\n$$ C_{\\text{surf,ss}} = \\left( \\frac{1}{\\frac{\\ln(2)}{t_{1/2}} + k_{\\text{int}}} \\right) \\left( \\frac{fR \\alpha M_{\\text{free}}}{d + \\alpha M_{\\text{free}}} \\right) $$\n\nNow, we evaluate this expression using the given parameter values:\n- $R = 100 \\text{ s}^{-1}$\n- $f = 0.30$\n- $d = 0.50 \\text{ s}^{-1}$\n- $M_{\\text{free}} = 1.0 \\times 10^{4}$\n- $\\alpha = 1.0 \\times 10^{-4} \\text{ s}^{-1} \\text{molecule}^{-1}$\n- $t_{1/2} = 3600 \\text{ s}$\n- $k_{\\text{int}} = 1.0 \\times 10^{-4} \\text{ s}^{-1}$\n\nFirst, we calculate the intermediate terms:\nThe rate of peptide binding in the ER:\n$$ \\alpha M_{\\text{free}} = (1.0 \\times 10^{-4} \\text{ s}^{-1}) \\times (1.0 \\times 10^{4}) = 1.0 \\text{ s}^{-1} $$\nThe rate of complex formation:\n$$ \\text{Rate}_{\\text{form}} = \\frac{fR (\\alpha M_{\\text{free}})}{d + \\alpha M_{\\text{free}}} = \\frac{(0.30)(100)(1.0)}{0.50 + 1.0} = \\frac{30}{1.5} = 20 \\text{ s}^{-1} $$\nThe dissociation rate constant:\n$$ k_{\\text{off}} = \\frac{\\ln(2)}{t_{1/2}} = \\frac{\\ln(2)}{3600} \\text{ s}^{-1} $$\nThe total loss rate constant for surface complexes:\n$$ k_{\\text{loss}} = k_{\\text{off}} + k_{\\text{int}} = \\frac{\\ln(2)}{3600} + 1.0 \\times 10^{-4} \\text{ s}^{-1} $$\nFinally, we calculate the steady-state number of surface complexes:\n$$ C_{\\text{surf,ss}} = \\frac{\\text{Rate}_{\\text{form}}}{k_{\\text{loss}}} = \\frac{20}{\\frac{\\ln(2)}{3600} + 1.0 \\times 10^{-4}} $$\n$$ C_{\\text{surf,ss}} = \\frac{20 \\times 3600}{\\ln(2) + 3600 \\times (1.0 \\times 10^{-4})} = \\frac{72000}{\\ln(2) + 0.36} $$\nUsing the value $\\ln(2) \\approx 0.693147$:\n$$ C_{\\text{surf,ss}} \\approx \\frac{72000}{0.693147 + 0.36} = \\frac{72000}{1.053147} \\approx 68369.34 $$\nRounding to three significant figures, the expected number of epitope-specific peptide–MHC I complexes per cell is $6.84 \\times 10^4$.\n\nAs requested, two factors or assumptions under which this estimate would be expected to fail are:\n1.  **Competition for MHC I molecules:** The model assumes $M_{\\text{free}}$ is constant. In an infected cell, thousands of different peptide species derived from both viral and host proteins compete for a finite pool of MHC I molecules. High concentrations of other peptides would deplete the available $M_{\\text{free}}$, reducing the binding probability for the specific epitope in question. This would lead to a lower surface abundance than predicted.\n2.  **Kinetics of intracellular transport:** The model implicitly assumes that transport of newly formed complexes from the ER to the cell surface is instantaneous. In reality, this trafficking through the secretory pathway (ER to Golgi to plasma membrane) involves a significant time delay, on the order of tens of minutes. This delay and potential inefficiencies (e.g., degradation during transit) are not modeled, and their inclusion would result in a lower predicted surface abundance and a lag in its appearance.",
            "answer": "$$ \\boxed{6.84 \\times 10^4} $$"
        },
        {
            "introduction": "Moving from the molecular level to the whole organism, the priming of naive T cells is a highly specialized process orchestrated in secondary lymphoid organs. Different subsets of dendritic cells (DCs) are adapted for distinct roles in initiating immune responses. This problem  asks you to predict the outcome of a classic in vivo experiment designed to probe the function of a specific DC subset, forcing you to think like an experimental immunologist. By analyzing the consequences of depleting XCR1$^+$ dendritic cells, you will explore the essential and non-redundant role of this cell type in cross-presenting cell-associated antigens to prime CD8$^+$ T cells.",
            "id": "4696817",
            "problem": "You are studying the role of the chemokine receptor XCR1-expressing dendritic cells in antiviral cytotoxic T-lymphocyte priming. Consider the following experimental design grounded in core principles of antigen presentation.\n\nFundamental base:\n- The Major Histocompatibility Complex class I (MHC I) pathway typically presents endogenous (cytosolic) antigens to naive cluster of differentiation 8-positive (CD8$^+$) T cells. Exogenous antigens can be displayed on MHC I via cross-presentation by specialized dendritic cells (DCs). Conventional dendritic cell subset 1 (cDC1), which is dependent on the transcription factor Basic Leucine Zipper ATF-Like Transcription Factor 3 (Batf3) and marked by XCR1, excels at cross-presentation of cell-associated antigens. In contrast, conventional dendritic cell subset 2 (cDC2) is optimized for Major Histocompatibility Complex class II (MHC II) presentation to CD4$^+$ T cells.\n- Priming of naive CD8$^+$ T cells against antigens that are restricted to non-hematopoietic parenchymal cells during viral infection relies on cross-presentation by cDC1, especially when the virus does not directly infect dendritic cells.\n\nExperiment:\n- Two groups of mice are used: control littermates and Xcr1-diphtheria toxin receptor transgenic mice treated with diphtheria toxin to selectively deplete XCR1$^+$ dendritic cells immediately prior to infection.\n- Mice are infected with a virus engineered to express a model antigen exclusively in radio-resistant, non-hematopoietic parenchymal cells; the virus does not infect dendritic cells.\n- Prior to infection, a small number of naive, T cell receptor (TCR)-transgenic, antigen-specific CD8$^+$ T cells are adoptively transferred. Proliferation and effector differentiation are measured in draining lymph nodes at day 3 and day 7 by dilution of carboxyfluorescein succinimidyl ester (CFSE), interferon-$\\gamma$ (IFN-$\\gamma$) production upon peptide restimulation, and acquisition of cytotoxic molecules (granzyme B).\n- In parallel, CD4$^+$ T-cell priming is assessed against an unrelated protein antigen delivered with the same infection, and viral loads are measured in target tissues.\n\nWhich of the following outcomes is most consistent with first principles of antigen presentation and known subset specialization?\n\nA. In the XCR1$^+$ dendritic cell-depleted group, primary priming of antigen-specific CD8$^+$ T cells to the parenchymal cell-associated antigen is nearly abolished, with markedly reduced proliferation, IFN-$\\gamma$ production, and cytotoxic T lymphocyte generation at days 3 and 7, leading to impaired early viral control; CD4$^+$ T-cell priming to the unrelated antigen is largely preserved.\n\nB. There is no measurable effect on antigen-specific CD8$^+$ T-cell priming because cDC2 and monocyte-derived dendritic cells fully compensate for loss of XCR1$^+$ dendritic cells in cross-presentation in vivo; viral control and CD4$^+$ responses are unchanged.\n\nC. Antigen-specific CD8$^+$ T-cell priming is enhanced in the XCR1$^+$ dendritic cell-depleted group because removal of this subset reduces antigen competition and increases access of cDC2 to cross-presented peptides, resulting in increased IFN-$\\gamma$ and granzyme B.\n\nD. Primary priming of antigen-specific CD8$^+$ T cells to the parenchymal cell-associated antigen proceeds normally in the absence of XCR1$^+$ dendritic cells, but recall expansion of memory CD8$^+$ T cells is selectively impaired at day 7; viral control is delayed only at later time points.",
            "solution": "### Problem Validation\n\n#### Step 1: Extract Givens\n\nThe problem statement provides the following information:\n\n**Fundamental Base:**\n1.  The Major Histocompatibility Complex class I (MHC I) pathway presents endogenous (cytosolic) antigens to naive cluster of differentiation 8-positive (CD8$^+$) T cells.\n2.  Exogenous antigens can be displayed on MHC I via a process called cross-presentation, performed by specialized dendritic cells (DCs).\n3.  Conventional dendritic cell subset 1 (cDC1), which is dependent on the transcription factor Batf3 and marked by the chemokine receptor XCR1, is specialized for cross-presentation of cell-associated antigens.\n4.  Conventional dendritic cell subset 2 (cDC2) is optimized for Major Histocompatibility Complex class II (MHC II) presentation to CD4$^+$ T cells.\n5.  Priming of naive CD8$^+$ T cells against antigens restricted to non-hematopoietic parenchymal cells during viral infection relies on cross-presentation by cDC1, particularly when the virus does not directly infect DCs.\n\n**Experimental Design:**\n1.  **Subject Groups:** Control littermates and Xcr1-diphtheria toxin receptor (DTR) transgenic mice treated with diphtheria toxin (DT) to selectively deplete XCR1$^+$ DCs.\n2.  **Infection Model:** Mice are infected with a virus engineered to express a model antigen *exclusively* in radio-resistant, non-hematopoietic parenchymal cells. The virus *does not* infect dendritic cells.\n3.  **T Cell Priming Assessment:** A small number of naive, T cell receptor (TCR)-transgenic, antigen-specific CD8$^+$ T cells are adoptively transferred before infection.\n4.  **Readouts:** Proliferation (CFSE dilution), effector function (interferon-$\\gamma$ (IFN-$\\gamma$) production), and cytotoxic molecule acquisition (granzyme B) are measured in draining lymph nodes at day 3 and day 7.\n5.  **Parallel Controls:** CD4$^+$ T-cell priming is assessed against an unrelated protein antigen. Viral loads are measured.\n\n#### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the validation criteria.\n\n*   **Scientifically Grounded:** The problem is firmly rooted in established principles of cellular immunology. The distinct roles of cDC1 and cDC2 subsets, the mechanisms of MHC class I and class II antigen presentation, the process of cross-presentation, and the requirements for priming naive T cells are all described in accordance with current scientific consensus. The experimental model, using Xcr1-DTR mice for conditional cell depletion and adoptive transfer of TCR-transgenic T cells, is a standard and widely accepted methodology in the field.\n*   **Well-Posed:** The problem is well-posed. It presents a clearly defined experimental scenario and asks for the most likely outcome based on the provided fundamental principles. The setup is designed to isolate the function of a single cell type (XCR1$^+$ DCs) in a specific immunological context, allowing for a logical and unique conclusion to be drawn.\n*   **Objective:** The language is technical, precise, and free of subjectivity or bias. It describes a hypothetical but standard scientific experiment.\n\nThere are no identifiable flaws:\n1.  **Scientific or Factual Unsoundness:** None. The premises are factually correct.\n2.  **Non-Formalizable or Irrelevant:** None. The problem is a direct application of biological principles to a formalizable experimental design.\n3.  **Incomplete or Contradictory Setup:** None. The problem is self-contained. The constraints—that the antigen is found only in parenchymal cells and the virus does not infect DCs—are critical and clearly stated, precluding ambiguity.\n4.  **Unrealistic or Infeasible:** None. While perfectly exclusive viral tropism is an idealization, it is a standard assumption in such theoretical and experimental models to dissect specific pathways. The Xcr1-DTR system is a real and validated tool.\n5.  **Ill-Posed or Poorly Structured:** None. All terms are standard and well-defined within immunology.\n6.  **Pseudo-Profound, Trivial, or Tautological:** None. The question requires a multi-step logical deduction based on an integrated understanding of several immunological concepts.\n\n#### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, and internally consistent. I will proceed to derive the solution.\n\n### Solution Derivation\n\nThe experiment is designed to test the necessity of XCR1$^+$ cDC1 cells for the primary activation of naive CD8$^+$ T cells against a viral antigen that is not directly available to antigen-presenting cells (APCs).\n\n1.  **Antigen Location and Presentation Pathway:** The viral antigen is produced endogenously within non-hematopoietic parenchymal cells. These infected cells will process the antigen and present peptides on their MHC class I molecules. However, parenchymal cells are not professional APCs and are inefficient at priming naive T cells, which typically occurs in secondary lymphoid organs.\n2.  **Requirement for Professional APCs:** For a robust primary T cell response, naive CD8$^+$ T cells must be activated by professional APCs, predominantly dendritic cells, in the draining lymph nodes.\n3.  **Antigen Acquisition by DCs:** Since the virus does not infect DCs, the DCs cannot produce the viral antigen endogenously. Therefore, they must acquire the antigen from an external source, specifically from the infected parenchymal cells (e.g., by taking up dead or dying infected cells or cell fragments). For the DC, this is an exogenous antigen.\n4.  **Cross-Presentation is Essential:** To prime naive CD8$^+$ T cells, the DC must present this exogenously acquired antigen on its MHC class I molecules. This process is known as cross-presentation.\n5.  **The Role of XCR1$^+$ cDC1:** The \"Fundamental base\" explicitly states that the cDC1 subset, marked by XCR1 expression, \"excels at cross-presentation of cell-associated antigens.\" The experimental setup perfectly matches this scenario: the antigen is cell-associated (in parenchymal cells). Therefore, XCR1$^+$ cDC1s are the principal cell type responsible for initiating the CD8$^+$ T cell response in this model.\n6.  **Effect of XCR1$^+$ DC Depletion:** In the experimental group, these critical XCR1$^+$ DCs are depleted. The absence of the primary cross-presenting cell population will prevent the antigen from being efficiently presented on MHC class I to the naive, adoptively transferred CD8$^+$ T cells in the lymph nodes.\n7.  **Consequences for CD8$^+$ T Cell Priming:** Without proper antigen presentation and co-stimulation from cDC1s, the naive CD8$^+$ T cells will fail to be primed. This will manifest as a lack of proliferation (no dilution of CFSE), a failure to differentiate into effector cells capable of producing IFN-$\\gamma$, and an inability to acquire cytotoxic machinery like granzyme B. This failure will be evident throughout the primary response phase, including at day 3 and day 7.\n8.  **Consequences for Viral Control:** Cytotoxic T Lymphocytes (CTLs), the effector form of CD8$^+$ T cells, are essential for killing virus-infected parenchymal cells. The failure to generate CTLs will result in an inability to control the viral infection, leading to higher viral loads compared to the control group.\n9.  **Control for CD4$^+$ T Cell Priming:** The priming of CD4$^+$ T cells is assessed against an unrelated protein antigen. This process relies on the presentation of exogenous antigens on MHC class II molecules. The \"Fundamental base\" states that cDC2s are \"optimized for Major Histocompatibility Complex class II (MHC II) presentation to CD4$^+$ T cells.\" Since the depletion targets XCR1$^+$ cDC1s, the cDC2 population remains largely intact and functional. Therefore, the priming of CD4$^+$ T cells should proceed normally. This serves as an internal control demonstrating the specificity of the defect to the cDC1-dependent pathway.\n\n### Option-by-Option Analysis\n\n*   **A. In the XCR1$^+$ dendritic cell-depleted group, primary priming of antigen-specific CD8$^+$ T cells to the parenchymal cell-associated antigen is nearly abolished, with markedly reduced proliferation, IFN-$\\gamma$ production, and cytotoxic T lymphocyte generation at days 3 and 7, leading to impaired early viral control; CD4$^+$ T-cell priming to the unrelated antigen is largely preserved.**\n    This statement aligns perfectly with all points of the derived solution. The depletion of XCR1$^+$ cDC1s ablates cross-presentation, which in turn abolishes CD8$^+$ T cell priming and its consequences (proliferation, effector function). This leads to failed viral control. The preserved CD4$^+$ T cell response confirms that the defect is specific to the cDC1-mediated pathway.\n    **Verdict: Correct.**\n\n*   **B. There is no measurable effect on antigen-specific CD8$^+$ T-cell priming because cDC2 and monocyte-derived dendritic cells fully compensate for loss of XCR1$^+$ dendritic cells in cross-presentation in vivo; viral control and CD4$^+$ responses are unchanged.**\n    This is incorrect. The premise of the problem and a large body of immunological evidence establishes a non-redundant, specialized role for XCR1$^+$ cDC1s in cross-presenting cell-associated antigens. While other APCs may have minimal cross-presenting capacity, they cannot \"fully compensate\" in this context. The experiment is designed specifically to highlight this lack of compensation.\n    **Verdict: Incorrect.**\n\n*   **C. Antigen-specific CD8$^+$ T-cell priming is enhanced in the XCR1$^+$ dendritic cell-depleted group because removal of this subset reduces antigen competition and increases access of cDC2 to cross-presented peptides, resulting in increased IFN-$\\gamma$ and granzyme B.**\n    This is incorrect. It posits that removing the most efficient cell for a task will enhance that task, which is biologically and logically flawed. cDC2s are poor cross-presenters compared to cDC1s. Removing cDC1s would critically impair, not enhance, the overall cross-presentation and subsequent CD8$^+$ T cell priming. The concept of \"reduced antigen competition\" leading to enhanced priming by a suboptimal cell type is not a recognized immunological principle in this context.\n    **Verdict: Incorrect.**\n\n*   **D. Primary priming of antigen-specific CD8$^+$ T cells to the parenchymal cell-associated antigen proceeds normally in the absence of XCR1$^+$ dendritic cells, but recall expansion of memory CD8$^+$ T cells is selectively impaired at day 7; viral control is delayed only at later time points.**\n    This is incorrect. The primary defect lies in the *primary priming* of naive cells, not a memory response. The experiment starts with naive T cells, and day 7 is still a key time point for measuring the primary effector response, not a memory recall phase. If primary priming were normal, the defect would not manifest as a failure of the day 7 response. The premise that priming proceeds normally is the fundamental error.\n    **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once a T cell is activated, its differentiation into a specific effector or regulatory lineage is governed by a complex intracellular gene regulatory network. This decision is not graded but is often a robust, all-or-none commitment. This computational exercise  guides you to model the core \"toggle switch\" between the pro-inflammatory T helper 17 (Th17) and anti-inflammatory regulatory T (Treg) fates. By implementing a simple dynamical system and analyzing its behavior, you will discover how cytokine signals and mutual transcriptional repression can generate bistability, a fundamental property that enables stable, switch-like cell fate decisions.",
            "id": "4696787",
            "problem": "You are to construct and analyze a minimal, dimensionless gene regulatory network for the fate decision between T helper 17 cells and regulatory T cells in the presence of Transforming Growth Factor beta (TGF-β) and Interleukin 6 (IL-6). The two master transcription factors are Forkhead Box P3 (FOXP3), denoted by the variable $x$, and Retinoic acid–related orphan receptor gamma t (ROR$\\gamma$t), denoted by the variable $y$. The model must be derived from fundamental principles of gene regulation: production is controlled by input signals via sigmoidal activation and mutual repression via sigmoidal inhibition, and removal is via first-order decay.\n\nStarting from the following well-tested bases:\n- The Central Dogma of molecular biology: signaling controls transcription factor production, which decays over time, leading to dynamic changes in concentrations.\n- Hill-type activation and repression are standard steady-state approximations capturing cooperative binding in transcriptional regulation.\n- Ordinary differential equations express the rate of change of transcription factor concentrations as production minus degradation.\n\nDefine the dynamics of $x$ and $y$ by:\n$$\n\\frac{dx}{dt} = \\left(b_x + a_{T} \\cdot H_{\\text{act}}(S_T;K_S,n_S)\\right)\\cdot H_{\\text{rep}}(y;K_{yx},n_{yx}) - d_x \\, x,\n$$\n$$\n\\frac{dy}{dt} = \\left(b_y + a_{S} \\cdot H_{\\text{act}}(S_L;K_S,n_S)\\cdot H_{\\text{act}}(S_T;K_S,n_S)\\right)\\cdot H_{\\text{rep}}(x;K_{xy},n_{xy}) - d_y \\, y,\n$$\nwhere $S_T$ is the dimensionless TGF-β level, $S_L$ is the dimensionless IL-6 level, $H_{\\text{act}}$ is a Hill activation function, and $H_{\\text{rep}}$ is a Hill repression function given by:\n$$\nH_{\\text{act}}(s;K,n) = \\frac{s^n}{K^n + s^n},\n\\quad\nH_{\\text{rep}}(z;K,n) = \\frac{1}{1 + \\left(\\frac{z}{K}\\right)^n}.\n$$\nAll variables and parameters are dimensionless. The constants $b_x$ and $b_y$ are basal production strengths, $a_{T}$ is the TGF-β-induced FOXP3 activation amplitude, $a_{S}$ is the synergy amplitude of Interleukin 6 (IL-6) and TGF-β for ROR$\\gamma$t, $K_S$ is the activation half-saturation constant for both signals, $n_S$ is the Hill coefficient for signal activation, $K_{xy}$ and $K_{yx}$ are the repression half-saturation constants, and $n_{xy}$ and $n_{yx}$ are the Hill coefficients for repression. The decay rates are $d_x$ and $d_y$.\n\nYour program must:\n1. Implement the above dynamical system.\n2. For each parameter set in the test suite, determine whether the system exhibits bistability by:\n   - Sampling a grid of initial conditions $(x(0),y(0))$ over a specified range.\n   - Integrating the dynamics to a steady state for each initial condition.\n   - Clustering the distinct asymptotic endpoints to count the number of stable attractors; report bistability if and only if there are at least two distinct, well-populated clusters (each cluster must contain at least three endpoints).\n3. Output a single line containing a list of booleans, where each boolean corresponds to a test case and is true if the system is bistable and false otherwise.\n\nUse the following fixed parameter values for all test cases:\n- $b_x = 0.02$, $b_y = 0.02$,\n- $a_{T} = 1.0$, $a_{S} = 2.0$,\n- $K_S = 0.5$, $n_S = 2$,\n- $K_{xy} = 0.2$, $K_{yx} = 0.2$,\n- $d_x = 1.0$, $d_y = 1.0$.\n\nTreat $S_T$, $S_L$, $n_{xy}$, and $n_{yx}$ as variables specified per test case.\n\nNumerical procedure requirements:\n- Initial condition grid: $x(0),y(0)$ uniformly sampled from $[0,1.5]$ with $11$ points per dimension.\n- Time integration: integrate from $t=0$ to $t=200$ (dimensionless time units); if the norm of derivatives at the endpoint exceeds $10^{-6}$, extend integration to $t=600$.\n- Endpoint clustering: two endpoints $(x_1,y_1)$ and $(x_2,y_2)$ belong to the same cluster if $\\sqrt{(x_1-x_2)^2 + (y_1-y_2)^2} < 0.05$. Count only clusters with at least $3$ members.\n\nTest suite (each case is a tuple $(S_T,S_L,n_{xy},n_{yx})$):\n- Case A (happy path, Treg favored, monostable): $(1.0, 0.01, 4, 4)$.\n- Case B (happy path, Th17 favored, monostable): $(0.5, 1.0, 4, 4)$.\n- Case C (bistability candidate, moderate signals, strong repression cooperativity): $(0.5, 0.5, 4, 4)$.\n- Case D (edge case, very low signals, monostable near basal): $(0.01, 0.01, 4, 4)$.\n- Case E (boundary condition, moderate signals, weak repression cooperativity): $(0.5, 0.5, 2, 2)$.\n\nYour program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets (e.g., \"[true,false,true,false,false]\"). The outputs must be lower-case booleans \"true\" or \"false\", where \"true\" denotes bistability and \"false\" denotes monostability. All quantities are dimensionless; no physical units or angles are involved in this problem.",
            "solution": "The problem requires an analysis of a dynamical system modeling the fate decision between T helper 17 (Th17) cells and regulatory T (Treg) cells. The state of the system is described by the dimensionless concentrations of two master transcription factors: $x$ for Forkhead Box P3 (FOXP3), indicative of the Treg lineage, and $y$ for Retinoic acid–related orphan receptor gamma t (ROR$\\gamma$t), indicative of the Th17 lineage. The core of the problem is to determine whether the system exhibits bistability for given sets of parameters.\n\nFirst, the problem is validated and deemed sound. It is scientifically grounded in the principles of systems biology, using ordinary differential equations (ODEs) and Hill kinetics to model a gene regulatory network. The problem is well-posed, providing all necessary equations, parameters, and a detailed numerical procedure, ensuring a unique, verifiable outcome. All terms are objective and clearly defined.\n\nThe governing equations for the concentrations $x(t)$ and $y(t)$ are:\n$$\n\\frac{dx}{dt} = \\left(b_x + a_{T} \\cdot H_{\\text{act}}(S_T;K_S,n_S)\\right)\\cdot H_{\\text{rep}}(y;K_{yx},n_{yx}) - d_x \\, x\n$$\n$$\n\\frac{dy}{dt} = \\left(b_y + a_{S} \\cdot H_{\\text{act}}(S_L;K_S,n_S)\\cdot H_{\\text{act}}(S_T;K_S,n_S)\\right)\\cdot H_{\\text{rep}}(x;K_{xy},n_{xy}) - d_y \\, y\n$$\nThese equations represent a balance between production and first-order decay (with rates $d_x$ and $d_y$). The production of each transcription factor is regulated by external signals—TGF-$\\beta$ ($S_T$) and IL-6 ($S_L$)—and by mutual repression between $x$ and $y$. The regulatory logic is captured by sigmoidal Hill functions:\n- $H_{\\text{act}}(s;K,n) = \\frac{s^n}{K^n + s^n}$ models activation, where a signal $s$ promotes production.\n- $H_{\\text{rep}}(z;K,n) = \\frac{1}{1 + \\left(\\frac{z}{K}\\right)^n}$ models repression, where a transcription factor $z$ inhibits production.\n\nBistability occurs when a system, for a single set of parameters, can settle into two distinct stable steady states (attractors). The final state depends on the system's initial condition. To determine if the system is bistable, we follow a computational approach:\n\n1.  **State-Space Exploration**: We cannot solve this nonlinear system analytically. Instead, we simulate its behavior from a representative set of initial conditions. A grid of $11 \\times 11 = 121$ initial points $(x(0), y(0))$ is uniformly sampled from the domain $[0, 1.5] \\times [0, 1.5]$.\n\n2.  **Numerical Integration**: For each initial condition, the system of ODEs is integrated forward in time until it reaches a steady state. We use a numerical solver from the `scipy.integrate` library. An initial integration is performed up to a dimensionless time $t=200$.\n\n3.  **Convergence Verification**: A system at a steady state has zero rates of change. We verify convergence by calculating the Euclidean norm of the derivative vector, $\\sqrt{(\\frac{dx}{dt})^2 + (\\frac{dy}{dt})^2}$, at the final point of the simulation. If this norm exceeds a tolerance of $10^{-6}$, it implies the system has not yet settled. In such cases, the integration is repeated from the same initial condition but for a longer duration, up to $t=600$, to ensure convergence.\n\n4.  **Attractor Identification via Clustering**: The resulting $121$ endpoint coordinates represent the attractors of the system. To count the number of distinct attractors, we cluster these points. Two endpoints $(x_1, y_1)$ and $(x_2, y_2)$ are considered to belong to the same attractor if the Euclidean distance between them is less than a threshold of $0.05$. That is, if $\\sqrt{(x_1-x_2)^2 + (y_1-y_2)^2} < 0.05$. This procedure groups all endpoints that have converged to the same region of the state space. This is equivalent to finding the connected components of a graph where the points are vertices and an edge exists between any two vertices closer than the threshold.\n\n5.  **Bistability Assessment**: The final step is to count the number of \"well-populated\" clusters, defined as those containing at least $3$ endpoints. The system is classified as bistable if and only if there are two or more such well-populated clusters. This condition ensures that the identified attractors are robust and not artifacts of single, isolated trajectories.\n\nThe provided Python code implements this entire workflow. For each test case specified in the problem, it executes these steps and determines whether the system is bistable, outputting the results as a list of boolean values.",
            "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\nfrom scipy.integrate import solve_ivp\n\ndef solve():\n    \"\"\"\n    Analyzes a gene regulatory network model for T-cell differentiation\n    to determine bistability across several parameter sets.\n    \"\"\"\n    \n    # Define fixed parameters for the model as dimensionless quantities.\n    FIXED_PARAMS = {\n        'b_x': 0.02, 'b_y': 0.02,\n        'a_T': 1.0, 'a_S': 2.0,\n        'K_S': 0.5, 'n_S': 2,\n        'K_xy': 0.2, 'K_yx': 0.2,\n        'd_x': 1.0, 'd_y': 1.0\n    }\n\n    # Define the test cases, each being a tuple of (S_T, S_L, n_xy, n_yx).\n    test_cases = [\n        (1.0, 0.01, 4, 4),  # Case A: Treg favored, monostable\n        (0.5, 1.0, 4, 4),   # Case B: Th17 favored, monostable\n        (0.5, 0.5, 4, 4),   # Case C: Bistability candidate\n        (0.01, 0.01, 4, 4), # Case D: Low signals, monostable basal\n        (0.5, 0.5, 2, 2),   # Case E: Weak repression cooperativity\n    ]\n\n    def h_act(s, k, n):\n        \"\"\"Hill activation function.\"\"\"\n        s_pow_n = s**n\n        return s_pow_n / (k**n + s_pow_n)\n\n    def h_rep(z, k, n):\n        \"\"\"Hill repression function.\"\"\"\n        return 1.0 / (1.0 + (z / k)**n)\n\n    def model_rhs(t, Z, s_t, s_l, n_xy, n_yx, p):\n        \"\"\"Right-hand side of the ODE system for the GRN.\"\"\"\n        x, y = Z\n        \n        # Production term for x (FOXP3)\n        prod_x_signal = p['b_x'] + p['a_T'] * h_act(s_t, p['K_S'], p['n_S'])\n        rep_on_x = h_rep(y, p['K_yx'], n_yx)\n        \n        # Production term for y (RORgt)\n        prod_y_signal = p['b_y'] + p['a_S'] * h_act(s_l, p['K_S'], p['n_S']) * h_act(s_t, p['K_S'], p['n_S'])\n        rep_on_y = h_rep(x, p['K_xy'], n_xy)\n        \n        dxdt = prod_x_signal * rep_on_x - p['d_x'] * x\n        dydt = prod_y_signal * rep_on_y - p['d_y'] * y\n        \n        return [dxdt, dydt]\n\n    def cluster_endpoints(points, threshold):\n        \"\"\"Clusters endpoints based on Euclidean distance.\"\"\"\n        n_points = len(points)\n        if n_points == 0:\n            return []\n        \n        # Build adjacency matrix based on proximity\n        adj = np.zeros((n_points, n_points), dtype=bool)\n        for i in range(n_points):\n            for j in range(i + 1, n_points):\n                dist = np.linalg.norm(points[i] - points[j])\n                if dist < threshold:\n                    adj[i, j] = adj[j, i] = True\n        \n        # Find connected components (clusters) using BFS\n        visited = [False] * n_points\n        clusters = []\n        for i in range(n_points):\n            if not visited[i]:\n                component_indices = []\n                queue = [i]\n                visited[i] = True\n                \n                head = 0\n                while head < len(queue):\n                    u = queue[head]\n                    head += 1\n                    component_indices.append(u)\n                    \n                    for v in range(n_points):\n                        if adj[u, v] and not visited[v]:\n                            visited[v] = True\n                            queue.append(v)\n                clusters.append([points[idx] for idx in component_indices])\n        return clusters\n\n    def check_bistability(params):\n        \"\"\"Performs the full numerical procedure to check for bistability.\"\"\"\n        s_t, s_l, n_xy, n_yx = params\n        \n        # Numerical procedure settings\n        ic_grid_points = 11\n        ic_range = np.linspace(0, 1.5, ic_grid_points)\n        t_span1 = [0, 200]\n        t_span2 = [0, 600]\n        deriv_tol = 1e-6\n        cluster_tol = 0.05\n        min_cluster_size = 3\n        \n        steady_states = []\n        \n        ode_func = lambda t, Z: model_rhs(t, Z, s_t, s_l, n_xy, n_yx, FIXED_PARAMS)\n\n        for x0 in ic_range:\n            for y0 in ic_range:\n                z0 = [x0, y0]\n                \n                # Integrate to t=200\n                sol1 = solve_ivp(ode_func, t_span1, z0, method='RK45', dense_output=True)\n                z_final = sol1.y[:, -1]\n                \n                # Check derivative norm for convergence\n                derivs = ode_func(t_span1[1], z_final)\n                norm_deriv = np.linalg.norm(derivs)\n                \n                # If not converged, re-integrate over a longer time span\n                if norm_deriv > deriv_tol:\n                    sol2 = solve_ivp(ode_func, t_span2, z0, method='RK45', dense_output=True)\n                    z_final = sol2.y[:, -1]\n                \n                steady_states.append(z_final)\n            \n        # Cluster the collected steady-state endpoints\n        clusters = cluster_endpoints(np.array(steady_states), cluster_tol)\n        \n        # Count well-populated clusters\n        well_populated_clusters = sum(1 for c in clusters if len(c) >= min_cluster_size)\n        \n        # Bistability is defined as having at least two well-populated clusters\n        return well_populated_clusters >= 2\n\n    results = []\n    for case in test_cases:\n        is_bistable = check_bistability(case)\n        results.append(str(is_bistable).lower())\n        \n    # Final print statement in the exact required format.\n    print(f\"[{','.join(results)}]\")\n\nsolve()\n```"
        }
    ]
}